Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

In vitro transcription studies used in a proof of concept whole transcriptome model predition study

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE109514 | GEO | 2018/12/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

In vitro transcription studies used in a proof of concept whole transcriptome model predition study - HepG2 cells (4 of 4)

Project description:HpeG2 cells were exposed in triplicate to three agrichemicals for 24hrs at 8 concentrations and a DMSO vehicle control (0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, and 10 μM plus DMSO vehicle controls). While a common set of DMSO controls was used, these CEL files were RMA normalized independently with each of the chemical treated groups. Gene expression was measured on an Affymetrix GeneTitan system. The compounds used were fenbuconazole (a.k.a FENB, CAS # 114369-43-6) a triazole fungicide, imazalil (a.k.a. IMAZ, CAS # 35554-44-0), an azole pesticide, and 2,4-dichlorophenoxyacetic acid (a.k.a. 2,4-D or 2-4-D in file names, CAS # 94-75-7), a chlorophenoxy herbicide.

2018-12-21 | GSE109513 | GEO

In vitro transcription studies used in a proof of concept whole transcriptome model predition study - HepaRG cells (3 of 4)

Project description:HepaRG cells were exposed in triplicate to three agrichemicals for 24hrs at 8 concentrations and a DMSO vehicle control (0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, and 10 μM plus DMSO vehicle controls). While a common set of DMSO controls was used, these CEL files were RMA normalized independently with each of the chemical treated groups. Gene expression was measured on an Affymetrix GeneTitan system. The compounds used were fenbuconazole (a.k.a FENB, CAS # 114369-43-6) a triazole fungicide, imazalil (a.k.a. IMAZ, CAS # 35554-44-0), an azole pesticide, and 2,4-dichlorophenoxyacetic acid (a.k.a. 2,4-D or 2-4-D in file names, CAS # 94-75-7), a chlorophenoxy herbicide.

2018-12-21 | GSE109511 | GEO

In vitro transcription studies used in a proof of concept whole transcriptome model predition study - MCF7 cells (2 of 4)

Project description:MCF7 cells were exposed in triplicate to three agrichemicals for 24hrs at 8 concentrations and a DMSO vehicle control (0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, and 10 μM plus DMSO vehicle controls). While a common set of DMSO controls was used, these CEL files were RMA normalized independently with each of the chemical treated groups. Gene expression was measured on an Affymetrix GeneTitan system. The compounds used were fenbuconazole (a.k.a FENB, CAS # 114369-43-6) a triazole fungicide, imazalil (a.k.a. IMAZ, CAS # 35554-44-0), an azole pesticide, and 2,4-dichlorophenoxyacetic acid (a.k.a. 2,4-D or 2-4-D in file names, CAS # 94-75-7), a chlorophenoxy herbicide.

2018-12-21 | GSE109509 | GEO

In vitro transcription studies used in a proof of concept whole transcriptome model predition study - A673 cells (1 of 4)

Project description:A673 cells were exposed in triplicate to three agrichemicals for 24hrs at 8 concentrations and a DMSO vehicle control (0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, and 10 μM plus DMSO vehicle controls). While a common set of DMSO controls was used, these CEL files were RMA normalized independently with each of the chemical treated groups. Gene expression was measured on an Affymetrix GeneTitan system. The compounds used were fenbuconazole (a.k.a FENB, CAS # 114369-43-6) a triazole fungicide, imazalil (a.k.a. IMAZ, CAS # 35554-44-0), an azole pesticide, and 2,4-dichlorophenoxyacetic acid (a.k.a. 2,4-D or 2-4-D in file names, CAS # 94-75-7), a chlorophenoxy herbicide. CEL files with _Rep2 in their file name indicate arrays that were re-scanned due to technical issues with the initial instrument scan of the GeneTitan peg array.

2018-12-21 | GSE109508 | GEO

In vitro transcription studies used in a proof of concept whole transcriptome model predition study

Project description:In vitro transcription studies used in a proof of concept whole transcriptome model predition study

| PRJNA431283 | ENA

In vitro transcription studies used in a proof of concept whole transcriptome model predition study - HepG2 cells (4 of 4)

Project description:In vitro transcription studies used in a proof of concept whole transcriptome model predition study - HepG2 cells (4 of 4)

| PRJNA431290 | ENA

In vitro transcription studies used in a proof of concept whole transcriptome model predition study - A673 cells (1 of 4)

Project description:In vitro transcription studies used in a proof of concept whole transcriptome model predition study - A673 cells (1 of 4)

| PRJNA431288 | ENA

In vitro transcription studies used in a proof of concept whole transcriptome model predition study - MCF7 cells (2 of 4)

Project description:In vitro transcription studies used in a proof of concept whole transcriptome model predition study - MCF7 cells (2 of 4)

| PRJNA431291 | ENA

In vitro transcription studies used in a proof of concept whole transcriptome model predition study - HepaRG cells (3 of 4)

Project description:In vitro transcription studies used in a proof of concept whole transcriptome model predition study - HepaRG cells (3 of 4)

| PRJNA431292 | ENA

Molecular phenotyping empowers drug discovery: a proof-of-concept study

Project description:Today, novel candidate therapeutics are identified in an environment which is intrinsically different from the clinical context in which they are ultimately evaluated. We present a strategy that allows biological relevance to be assessed in the early stages of drug discovery. Using molecular phenotyping and an in vitro model of diabetic cardiomyopathy, we show that by quantifying pathway reporter gene expression, molecular phenotyping can cluster compounds based on pathway profiles and dissect associations between pathway activities and disease phenotypes simultaneously. Molecular phenotyping identified a class of calcium-signaling modulators that can reverse disease-regulated pathways and phenotypes, which was validated by structurally distinct compounds of relevant classes. The technique was applicable to compounds with a range of binding specificities and detected false-positive hits missed by classical phenotypic assays. Our results advocate application of molecular phenotyping in drug discovery, promoting biological relevance as a key selection criterion early in the drug development cascade.

2017-05-24 | GSE89972 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data